<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35727573</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6211</ISSN><JournalIssue CitedMedium="Internet"><Volume>176</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA pediatrics</Title><ISOAbbreviation>JAMA Pediatr</ISOAbbreviation></Journal><ArticleTitle>Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>860</StartPage><EndPage>866</EndPage><MedlinePgn>860-866</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapediatrics.2022.1973</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The efficacy of multispecies probiotic formulations in the prevention of antibiotic-associated diarrhea (AAD) remains unclear.</AbstractText><AbstractText Label="OBJECTIVE">To assess the effect of a multispecies probiotic on the risk of AAD in children.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This randomized, quadruple-blind, placebo-controlled trial was conducted from February 2018 to May 2021 in a multicenter, mixed setting (inpatients and outpatients). Patients were followed up throughout the intervention period. Eligibility criteria included age 3 months to 18 years, recruitment within 24 hours following initiation of broad-spectrum systemic antibiotics, and signed informed consent. In total, 646 eligible patients were approached and 350 patients took part in the trial.</AbstractText><AbstractText Label="INTERVENTIONS">A multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, L acidophilus W55, Lacticaseibacillus paracasei W20, Lactiplantibacillus plantarum W62, Lacticaseibacillus rhamnosus W71, and Ligilactobacillus salivarius W24, for a total dose of 10 billion colony-forming units daily, for the duration of antibiotic treatment and for 7 days after.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was AAD, defined as 3 or more loose or watery stools per day in a 24-hour period, caused either by Clostridioides difficile or of otherwise unexplained etiology, after testing for common diarrheal pathogens. The secondary outcomes included diarrhea regardless of the etiology, diarrhea duration, and predefined diarrhea complications.</AbstractText><AbstractText Label="RESULTS">A total of 350 children (192 boys and 158 girls; mean [range] age, 50 [3-212] months) were randomized and 313 were included in the intention-to-treat analysis. Compared with placebo (n&#x2009;=&#x2009;155), the probiotic (n&#x2009;=&#x2009;158) had no effect on risk of AAD (relative risk [RR], 0.81; 95% CI, 0.49-1.33). However, children in the probiotic group had a lower risk of diarrhea regardless of the etiology (RR, 0.65; 95% CI, 0.44-0.94). No differences were observed between the groups for most of the secondary outcomes, including adverse events.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">A multispecies probiotic did not reduce the risk of AAD in children when analyzed according to the most stringent definition. However, it reduced the overall risk of diarrhea during and for 7 days after antibiotic treatment. Our study also shows that the AAD definition has a significant effect on clinical trial results and their interpretation.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT03334604.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lukasik</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, The Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dierikx</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, Academic Medical Centre, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besseling-van der Vaart</LastName><ForeName>Isolde</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Winclove Probiotics B.V., Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Meij</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, Academic Medical Centre, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szajewska</LastName><ForeName>Hania</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, The Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Multispecies Probiotic in AAD Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03334604</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Pediatr</MedlineTA><NlmUniqueID>101589544</NlmUniqueID><ISSNLinking>2168-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Pediatr. 2022 Sep 1;176(9):948. doi: 10.1001/jamapediatrics.2022.2527.</RefSource><PMID Version="1">35788632</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="Y">Diarrhea</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr &#x141;ukasik reported nonfinancial support from Winclove Probiotics B.V. Dr Dierikx reported grants and nonfinancial support from Winclove Probiotics B.V. Dr de Meij reported grants and nonfinancial support from Winclove B.V. Dr Szajewska reported nonfinancial support from Winclove B.V.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>van der Schoor</LastName><ForeName>Sophie R D</ForeName><Initials>SRD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chegary</LastName><ForeName>Malika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koning</LastName><ForeName>Catharina Karen J M</ForeName><Initials>CKJM</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35727573</ArticleId><ArticleId IdType="pmc">PMC9214631</ArticleId><ArticleId IdType="doi">10.1001/jamapediatrics.2022.1973</ArticleId><ArticleId IdType="pii">2793114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Turck D, Bernet JP, Marx J, et al. . Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003;37(1):22-26. doi:10.1097/00005176-200307000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005176-200307000-00004</ArticleId><ArticleId IdType="pubmed">12827001</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4(4):CD004827. doi:10.1002/14651858.CD004827.pub5</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004827.pub5</ArticleId><ArticleId IdType="pmc">PMC6490796</ArticleId><ArticleId IdType="pubmed">31039287</ArticleId></ArticleIdList></Reference><Reference><Citation>Szajewska H, Canani RB, Guarino A, et al. ; ESPGHAN Working Group for ProbioticsPrebiotics . Probiotics for the prevention of antibiotic-associated diarrhea in children. J Pediatr Gastroenterol Nutr. 2016;62(3):495-506. doi:10.1097/MPG.0000000000001081</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001081</ArticleId><ArticleId IdType="pubmed">26756877</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao W, Chen C, Wen T, Zhao Q. Probiotics for the prevention of antibiotic-associated diarrhea in adults: a meta-analysis of randomized placebo-controlled trials. J Clin Gastroenterol. 2021;55(6):469-480. doi:10.1097/MCG.0000000000001464</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000001464</ArticleId><ArticleId IdType="pmc">PMC8183490</ArticleId><ArticleId IdType="pubmed">33234881</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x141;ukasik J, Guo Q, Boulos L, Szajewska H, Johnston BC. Probiotics for the prevention of antibiotic-associated adverse events in children-a scoping review to inform development of a core outcome set. PLoS One. 2020;15(5):e0228824. doi:10.1371/journal.pone.0228824</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0228824</ArticleId><ArticleId IdType="pmc">PMC7259577</ArticleId><ArticleId IdType="pubmed">32469907</ArticleId></ArticleIdList></Reference><Reference><Citation>Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol. 2004;42(3):1203-1206. doi:10.1128/JCM.42.3.1203-1206.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.42.3.1203-1206.2004</ArticleId><ArticleId IdType="pmc">PMC356823</ArticleId><ArticleId IdType="pubmed">15004076</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563-578. doi:10.2217/17460913.3.5.563</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/17460913.3.5.563</ArticleId><ArticleId IdType="pubmed">18811240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Guarner F, Reid G, et al. . Expert consensus document. The International Scientific Association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. doi:10.1038/nrgastro.2014.66</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad K, Fatemeh F, Mehri N, Maryam S. Probiotics for the treatment of pediatric helicobacter pylori infection: a randomized double blind clinical trial. Iran J Pediatr. 2013;23(1):79-84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3574996</ArticleId><ArticleId IdType="pubmed">23446685</ArticleId></ArticleIdList></Reference><Reference><Citation>Saneeyan H, Layegh S, Rahimi H. Effectiveness of probiotic on treatment of Helicobacter pylori infection in children. Majallah-i Danishkadah-i Pizishki-i Isfahan. 2011;146(29):882-889.</Citation></Reference><Reference><Citation>Merenstein DJ, Foster J, D&#x2019;Amico F. A randomized clinical trial measuring the influence of kefir on antibiotic-associated diarrhea: the Measuring the Influence of Kefir (MILK) study. Arch Pediatr Adolesc Med. 2009;163(8):750-754. doi:10.1001/archpediatrics.2009.119</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpediatrics.2009.119</ArticleId><ArticleId IdType="pubmed">19652108</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway S, Hart A, Clark A, Harvey I. Does eating yogurt prevent antibiotic-associated diarrhoea? a placebo-controlled randomised controlled trial in general practice. Br J Gen Pract. 2007;57(545):953-959. doi:10.3399/096016407782604811</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/096016407782604811</ArticleId><ArticleId IdType="pmc">PMC2084134</ArticleId><ArticleId IdType="pubmed">18252070</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharnai S, Nirmala P, Ramanathan R, Vanitha S. Comparative study of efficacy and safety of azithromycin alone and in combination with probiotic in the treatment of impetigo in children. Int J Curr Pharm Res. 2017;9(6):52-55. doi:10.22159/ijcpr.2017v9i6.23429</Citation><ArticleIdList><ArticleId IdType="doi">10.22159/ijcpr.2017v9i6.23429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakordonets L, Tolstanova G, Yankovskiy D, Dyment H, Kramarev S. Different regimes of multiprobiotic for prevention of immediate and delayed side effects of antibiotic therapy In children. Res J Pharm Biol Chem Sci. 2016;7(3):2194-2201.</Citation></Reference><Reference><Citation>Koning CJ, Jonkers DM, Stobberingh EE, Mulder L, Rombouts FM, Stockbr&#xfc;gger RW. The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin. Am J Gastroenterol. 2008;103(1):178-189. doi:10.1111/j.1572-0241.2007.01547.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2007.01547.x</ArticleId><ArticleId IdType="pubmed">17900321</ArticleId></ArticleIdList></Reference><Reference><Citation>Koning CJ, Jonkers D, Smidt H, et al. . The effect of a multispecies probiotic on the composition of the faecal microbiota and bowel habits in chronic obstructive pulmonary disease patients treated with antibiotics. Br J Nutr. 2010;103(10):1452-1460. doi:10.1017/S0007114509993497</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114509993497</ArticleId><ArticleId IdType="pubmed">20021703</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x141;ukasik J, Szajewska H. Effect of a multispecies probiotic on reducing the incidence of antibiotic-associated diarrhoea in children: a protocol for a randomised controlled trial. BMJ Open. 2018;8(5):e021214. doi:10.1136/bmjopen-2017-021214</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-021214</ArticleId><ArticleId IdType="pmc">PMC5988056</ArticleId><ArticleId IdType="pubmed">29866789</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D; CONSORT Group . CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi:10.1136/bmj.c332</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c332</ArticleId><ArticleId IdType="pmc">PMC2844940</ArticleId><ArticleId IdType="pubmed">20332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanma A, Puttemans K, Deneyer M, Benninga MA, Vandenplas Y. Amsterdam infant stool scale is more useful for assessing children who have not been toilet trained than Bristol Stool Scale. Acta Paediatr. 2014;103(2):e91-e92. doi:10.1111/apa.12422</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.12422</ArticleId><ArticleId IdType="pubmed">24107091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis SJ, Heaton KW. Stool Form Scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920-924. doi:10.3109/00365529709011203</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365529709011203</ArticleId><ArticleId IdType="pubmed">9299672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruszczy&#x144;ski M, Radzikowski A, Szajewska H. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther. 2008;28(1):154-161. doi:10.1111/j.1365-2036.2008.03714.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03714.x</ArticleId><ArticleId IdType="pubmed">18410562</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(5):583-590. doi:10.1111/j.1365-2036.2005.02356.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02356.x</ArticleId><ArticleId IdType="pubmed">15740542</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials&#x2014;a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162. doi:10.1186/s12874-017-0442-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-017-0442-1</ArticleId><ArticleId IdType="pmc">PMC5717805</ArticleId><ArticleId IdType="pubmed">29207961</ArticleId></ArticleIdList></Reference><Reference><Citation>Akl EA, Briel M, You JJ, et al. . Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ. 2012;344:e2809. doi:10.1136/bmj.e2809</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e2809</ArticleId><ArticleId IdType="pubmed">22611167</ArticleId></ArticleIdList></Reference><Reference><Citation>Gozalbo-Rovira R, Rubio-Del-Campo A, Santiso-Bell&#xf3;n C, et al. . Interaction of intestinal bacteria with human rotavirus during infection in children. Int J Mol Sci. 2021;22(3):1010. doi:10.3390/ijms22031010</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031010</ArticleId><ArticleId IdType="pmc">PMC7864024</ArticleId><ArticleId IdType="pubmed">33498321</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchiyama R, Chassaing B, Zhang B, Gewirtz AT. Antibiotic treatment suppresses rotavirus infection and enhances specific humoral immunity. J Infect Dis. 2014;210(2):171-182. doi:10.1093/infdis/jiu037</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu037</ArticleId><ArticleId IdType="pmc">PMC4399425</ArticleId><ArticleId IdType="pubmed">24436449</ArticleId></ArticleIdList></Reference><Reference><Citation>Hojsak I, Szajewska H, Canani RB, et al. ; ESPGHAN Working Group for Probiotics/Prebiotics . Probiotics for the prevention of nosocomial diarrhea in children. J Pediatr Gastroenterol Nutr. 2018;66(1):3-9. doi:10.1097/MPG.0000000000001637</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001637</ArticleId><ArticleId IdType="pubmed">28574970</ArticleId></ArticleIdList></Reference><Reference><Citation>Za&#x142;&#x119;ski A, Banasiuk M, Karpierz K, Kuchar E, Podsiad&#x142;y E. The clinical course of gastroenteritis due to nosocomial and community acquired norovirus infections in immunocompromised and immunocompetent children&#x2014;single center experience. Przegl Epidemiol. 2020;74(1):23-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">32500981</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogilvie I, Khoury H, Goetghebeur MM, El Khoury AC, Giaquinto C. Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review. BMC Infect Dis. 2012;12:62. doi:10.1186/1471-2334-12-62</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-12-62</ArticleId><ArticleId IdType="pmc">PMC3342230</ArticleId><ArticleId IdType="pubmed">22429601</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino A, Ashkenazi S, Gendrel D, Lo Vecchio A, Shamir R, Szajewska H; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; European Society for Pediatric Infectious Diseases . European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr. 2014;59(1):132-152. doi:10.1097/MPG.0000000000000375</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000000375</ArticleId><ArticleId IdType="pubmed">24739189</ArticleId></ArticleIdList></Reference><Reference><Citation>Groenwold RH, Moons KG, Vandenbroucke JP. Randomized trials with missing outcome data: how to analyze and what to report. CMAJ. 2014;186(15):1153-1157. doi:10.1503/cmaj.131353</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.131353</ArticleId><ArticleId IdType="pmc">PMC4203602</ArticleId><ArticleId IdType="pubmed">24778353</ArticleId></ArticleIdList></Reference><Reference><Citation>Little RJ, D&#x2019;Agostino R, Cohen ML, et al. . The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355-1360. doi:10.1056/NEJMsr1203730</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsr1203730</ArticleId><ArticleId IdType="pmc">PMC3771340</ArticleId><ArticleId IdType="pubmed">23034025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby A, Iturriza-G&#xf3;mara M. Norovirus diagnostics: options, applications and interpretations. Expert Rev Anti Infect Ther. 2012;10(4):423-433. doi:10.1586/eri.12.21</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eri.12.21</ArticleId><ArticleId IdType="pubmed">22512752</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18026577</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0835-7900</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Canadian journal of gastroenterology = Journal canadien de gastroenterologie</Title><ISOAbbreviation>Can J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>732</StartPage><EndPage>736</EndPage><MedlinePgn>732-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Antibiotic-associated diarrhea is an important problem in hospitalized patients. The use of probiotics is gaining interest in the scientific community as a potential measure to prevent this complication. The main objective of the present study was to assess the efficacy and safety of a fermented milk combining Lactobacillus acidophilus and Lactobacillus casei that is widely available in Canada, in the prevention of antibiotic-associated diarrhea.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this double-blind, randomized study, hospitalized patients were randomly assigned to receive either a lactobacilli-fermented milk or a placebo on a daily basis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 89 randomized patients, antibiotic-associated diarrhea occurred in seven of 44 patients (15.9%) in the lactobacilli group and in 16 of 45 patients (35.6%) in the placebo group (OR 0.34, 95% CI 0.125 to 0.944; P=0.05). The median hospitalization duration was eight days in the lactobacilli group, compared with 10 days in the placebo group (P=0.09). Overall, the lactobacilli-fermented milk was well tolerated.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The daily administration of a lactobacilli-fermented milk was safe and effective in the prevention of antibiotic-associated diarrhea in hospitalized patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beausoleil</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University of Montreal, Montreal, Canada. mbeausoleil.hmr@ssss.gouv.qc.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortier</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Gu&#xe9;nette</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>L'ecuyer</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Savoie</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Franco</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lachaine</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can J Gastroenterol</MedlineTA><NlmUniqueID>8807867</NlmUniqueID><ISSNLinking>0835-7900</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>ACP J Club. 2008 Jul;149(1):10.</RefSource><PMID Version="1">18624378</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005285" MajorTopicYN="N">Fermentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007779" MajorTopicYN="Y">Lactobacillus acidophilus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007780" MajorTopicYN="Y">Lacticaseibacillus casei</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008892" MajorTopicYN="N">Milk</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText Label="HISTORIQUE :">La diarrh&#xe9;e associ&#xe9;e &#xe0; la prise d&#x2019;antibiotiques est un important probl&#xe8;me chez les patients hospitalis&#xe9;s. L&#x2019;utilisation de probiotiques gagne en popularit&#xe9; dans la communaut&#xe9; scientifique, &#xe0; titre de mesure potentielle de pr&#xe9;vention de cette complication. Le principal objectif de la pr&#xe9;sente &#xe9;tude &#xe9;tait d&#x2019;&#xe9;valuer l&#x2019;efficacit&#xe9; et l&#x2019;innocuit&#xe9; d&#x2019;un lait ferment&#xe9; alliant <i>Lactobacillus acidophilus</i> et <i>Lactobacillus casei</i>, facile &#xe0; se procurer au Canada, pour la pr&#xe9;vention de la diarrh&#xe9;e associ&#xe9;e &#xe0; la prise d&#x2019;antibiotiques.</AbstractText><AbstractText Label="M&#xc9;THODES :">Lors de cette &#xe9;tude &#xe0; double insu et randomis&#xe9;e, des patients hospitalis&#xe9;s ont &#xe9;t&#xe9; assign&#xe9;s al&#xe9;atoirement soit &#xe0; un lait ferment&#xe9; par lactobacilles, soit &#xe0; un placebo, sur une base quotidienne.</AbstractText><AbstractText Label="R&#xc9;SULTATS :">Parmi les 89 patients randomis&#xe9;s, la diarrh&#xe9;e associ&#xe9;e &#xe0; la prise d&#x2019;antibiotiques est survenue chez 7 patients sur 44 (15,9 %) du groupe sous lactobacilles et chez 16 patients sur 45 (35,6 %) du groupe sous placebo (RR 0,34, IC 95 % 0,125 &#xe0; 0,944; p = 0,05). La dur&#xe9;e m&#xe9;diane de l&#x2019;hospitalisation a &#xe9;t&#xe9; de huit jours dans le groupe sous lactobacilles, contre dix jours dans le groupe sous placebo (p = 0,09). Dans l&#x2019;ensemble, le lait ferment&#xe9; par lactobacilles a &#xe9;t&#xe9; bien tol&#xe9;r&#xe9;.</AbstractText><AbstractText Label="CONCLUSION :">L&#x2019;administration quotidienne d&#x2019;un lait ferment&#xe9; par lactobacilles s&#x2019;est r&#xe9;v&#xe9;l&#xe9;e s&#xe9;curitaire et efficace pour la pr&#xe9;vention de la diarrh&#xe9;e associ&#xe9;e &#xe0; la prise d&#x2019;antibiotiques chez les patients hospitalis&#xe9;s.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18026577</ArticleId><ArticleId IdType="pmc">PMC2658588</ArticleId><ArticleId IdType="doi">10.1155/2007/720205</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>H&#xf6;genauer C, Hammer HF, Krejs GJ, Reisinger EC. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis. 1998;27:702&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">9798020</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M, for the Canadian Hospital Epidemiology Committee Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol. 2002;23:137&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">11918118</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett JG. Clinical Practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11821511</ArticleId></ArticleIdList></Reference><Reference><Citation>Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ. 2004;171:51&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC437686</ArticleId><ArticleId IdType="pubmed">15238498</ArticleId></ArticleIdList></Reference><Reference><Citation>Siitonen S, Vapaatalo H, Salminen S, et al. Effect of Lactobacillus GG yoghurt in the prevention of antibiotic associated diarrhoea. Ann Med. 1990;22:57&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2184848</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremonini F, Di Caro S, Nista EC, et al. Meta-analysis: The effect of probiotic administration on antibiotic-associated diarrhea. Aliment Pharmacol Ther. 2002;16:1461&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12182746</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: Present knowledge and future prospects. Curr Pharm Des. 2003;9:175&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">12570667</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Canada. Overview of the natural health products regulations guidance document. &lt;http://www.hc-sc.gc.ca/dhp-mps/prodnatur/legislation/docs/regula-regle_over-apercu_e.html&gt;. (Version current at October 11, 2007).</Citation></Reference><Reference><Citation>Thomas MR, Litin SC, Osmon DR, Corr AP, Weaver AL, Lohse CM. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: A randomized, placebo-controlled trial. Mayo Clin Proc. 2001;76:883&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11560298</ArticleId></ArticleIdList></Reference><Reference><Citation>Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF. Double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhoea. DICP. 1990;24:382&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">2109432</ArticleId></ArticleIdList></Reference><Reference><Citation>Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2001;15:163&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148433</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol. 1995;90:439&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">7872284</ArticleId></ArticleIdList></Reference><Reference><Citation>Isolauri E, S&#xfc;tas Y, Kankaanpaa P, Arvilommi H, Salminen S. Probiotics: Effects on immunity. Am J Clin Nutr. 2001;73(2 Suppl):444S&#x2013;50S.</Citation><ArticleIdList><ArticleId IdType="pubmed">11157355</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Olmos MI, Oberhelman RA. Probiotic agents and infectious diseases: A modern perspective on a traditional therapy. Clin Infect Dis. 2001;32:1567&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">11340528</ArticleId></ArticleIdList></Reference><Reference><Citation>Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii. Gastroenterology. 1989;96:981&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2494098</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: A randomized study Pediatrics 1999104e64(Abst).</Citation><ArticleIdList><ArticleId IdType="pubmed">10545590</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect. 1998;36:171&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9570649</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz V, Romankiewicz JA, Moss J, Murray HW. Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation. Am J Hosp Pharm. 1979;36:754&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">111546</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam J, Barret A, Barret-Bellet C. Essais cliniques contr&#xf4;l&#xe9;s en double insu de l'Ultra-levure lyophilis&#xe9;e: &#xe9;tude multicentrique par 25 m&#xe9;decins de 388 cas. Gaz Med Fr. 1977;84:2072&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">796598</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: Meta-analysis. BMJ. 2002;324:1361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC115209</ArticleId><ArticleId IdType="pubmed">12052801</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderhoof JA, Young RJ. Use of probiotics in childhood gastrointestinal disorders. J Pediatr Gastroenterol Nutr. 1998;27:323&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9740206</ArticleId></ArticleIdList></Reference><Reference><Citation>Borriello SP, Hammes P, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36:775&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">12627362</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoddart B, Wilcox MH. Clostridium difficile. Curr Opin Infect Dis. 2002;15:513&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12686885</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998;16(5):292&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">9892789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis SJ, Freedman AR. Review article: The use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther. 1998;12:807&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9768523</ArticleId></ArticleIdList></Reference><Reference><Citation>Valiquette L, Low DE, Pepin J, McGeer A. Clostridium difficile infection in hospitals: A brewing storm. CMAJ. 2004;171:27&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC437677</ArticleId><ArticleId IdType="pubmed">15238490</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggertson L, Sibbald B. Hospitals battling outbreaks of C. difficile. CMAJ. 2004;171(1):19&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC437667</ArticleId><ArticleId IdType="pubmed">15238481</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30439760</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-2031</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Season>Nov/Dec</Season></PubDate></JournalIssue><Title>Journal of clinical gastroenterology</Title><ISOAbbreviation>J Clin Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Probiotic Yogurt for the Prevention of Antibiotic-associated Diarrhea in Adults: A Randomized Double-blind Placebo-controlled Trial.</ArticleTitle><Pagination><StartPage>717</StartPage><EndPage>723</EndPage><MedlinePgn>717-723</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MCG.0000000000001131</ELocationID><Abstract><AbstractText Label="GOAL">To evaluate the effect of yogurt supplemented with probiotic bacteria on the prevention of antibiotic-associated diarrhea (AAD) in hospitalized patients.</AbstractText><AbstractText Label="BACKGROUND">Diarrhea following antibiotic administration is a frequent clinical problem. The usefulness of probiotics for the prevention of AAD in the hospitalized adult population remains unclear.</AbstractText><AbstractText Label="STUDY">A randomized, double-blind, placebo-controlled clinical trial was conducted in hospitalized patients who started antibiotic treatment. Patients were randomized (2:2:1) to receive a daily amount of 200&#x2009;mL of placebo-yogurt (Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus), 200&#x2009;mL of probiotic yogurt (previous plus Lactobacillus acidophilus La-5, Bifidobacterium animalis subsp. lactis Bb-12 and Lactobacillus casei subsp. casei Lc-01 or no yogurt (unblinded control) within 48 hours of beginning the antibiotic therapy and up to 5 days after stopping the antibiotic. Patients were followed up with for 1 month to determine occurrence of diarrhea.</AbstractText><AbstractText Label="RESULTS">We included 314 patients, mean age 76 years. The rate of diarrhea was 23.0% in the probiotic group versus 17.6% in the placebo group, absolute risk reduction -5.35% (95% confidence interval, -15.4% to 4.7%; P=0.30). Rate of diarrhea was similar in the unblinded external control and in the blinded study groups combined (20.9% vs. 20.2% respectively; P=0.91). There was no difference in the duration of diarrhea, maximum number of bowel movements or prolonged admission because of diarrhea among the groups. All-cause mortality did not differ between groups.</AbstractText><AbstractText Label="CONCLUSIONS">The combined probiotic strains LA-5, BB-12, and LC-01 do not have an effect in the prevention of AAD in hospitalized patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Velasco</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Section, Internal Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Requena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biotechnology and Food Microbiology, Institute of Food Science Research CIAL, Consejo Superior de Investigaciones Cient&#xed;ficas CSIC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delgado-Iribarren</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Microbiology Department, Hospital Universitario Fundaci&#xf3;n Alcorc&#xf3;n, Alcorc&#xf3;n.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pel&#xe1;ez</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biotechnology and Food Microbiology, Institute of Food Science Research CIAL, Consejo Superior de Investigaciones Cient&#xed;ficas CSIC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guijarro</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Diseases Section, Internal Medicine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Gastroenterol</MedlineTA><NlmUniqueID>7910017</NlmUniqueID><ISSNLinking>0192-0790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015014" MajorTopicYN="Y">Yogurt</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30439760</ArticleId><ArticleId IdType="doi">10.1097/MCG.0000000000001131</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20145608</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1572-0241</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>7</Issue><PubDate><Year>2010</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of gastroenterology</Title><ISOAbbreviation>Am J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients.</ArticleTitle><Pagination><StartPage>1636</StartPage><EndPage>1641</EndPage><MedlinePgn>1636-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ajg.2010.11</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Standard therapies for antibiotic-associated diarrhea (AAD) and Clostridium difficile-associated diarrhea (CDAD) have limited efficacy. Probiotic prophylaxis is a promising alternative for reduction of AAD and CDAD incidence.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this single-center, randomized, double-blind, placebo-controlled dose-ranging study, we randomized 255 adult inpatients to one of three groups: two probiotic capsules per day (Pro-2, n=86), one probiotic capsule and one placebo capsule per day (Pro-1, n=85), or two placebo capsules per day (n=84). Each probiotic capsule contained 50 billion c.f.u. of live organisms (Lactobacillus acidophilus CL1285 +Lactobacillus casei LBC80R Bio-K+ CL1285). Probiotic prophylaxis began within 36 h of initial antibiotic administration, continued for 5 days after the last antibiotic dose, and patients were followed for an additional 21 days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Pro-2 (15.5%) had a lower AAD incidence vs. Pro-1 (28.2%). Each probiotic group had a lower AAD incidence vs. placebo (44.1%). In patients who acquired AAD, Pro-2 (2.8 days) and Pro-1 (4.1 days) had shorter symptom duration vs. placebo (6.4 days). Similarly, Pro-2 (1.2%) had a lower CDAD incidence vs. Pro-1 (9.4%). Each treatment group had a lower CDAD incidence vs. placebo (23.8%). Gastrointestinal symptoms were less common in the treatment groups vs. placebo and in Pro-2 vs. Pro-1.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The proprietary probiotic blend used in this study was well tolerated and effective for reducing risk of AAD and, in particular, CDAD in hospitalized patients on antibiotics. A dose-ranging effect was shown with 100 billion c.f.u., yielding superior outcomes and fewer gastrointestinal events compared to 50 billion c.f.u. (ClinicalTrials.gov number NCT00958308).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xing Wang</ForeName><Initials>XW</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Xinhua/Yuyao Hospital, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mubasher</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Chong Yu</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Reifer</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Larry E</ForeName><Initials>LE</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00958308</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>02</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Gastroenterol</MedlineTA><NlmUniqueID>0421030</NlmUniqueID><ISSNLinking>0002-9270</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Gastroenterol. 2011 Apr;106(4):804. doi: 10.1038/ajg.2010.494.</RefSource><PMID Version="1">21468077</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004761" MajorTopicYN="N">Enterocolitis, Pseudomembranous</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007779" MajorTopicYN="Y">Lactobacillus acidophilus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007780" MajorTopicYN="Y">Lacticaseibacillus casei</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20145608</ArticleId><ArticleId IdType="doi">10.1038/ajg.2010.11</ArticleId><ArticleId IdType="pii">ajg201011</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24291194</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Jan</Month><Day>16</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study.</ArticleTitle><Pagination><StartPage>458</StartPage><EndPage>463</EndPage><MedlinePgn>458-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2013.11.053</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(13)01587-9</ELocationID><Abstract><AbstractText>Probiotics are known to reduce antibiotic associated diarrhea (AAD) and Clostridium difficile associated diarrhea (CDAD) risk in a strain-specific manner. The aim of this study was to determine the dose-response effect of a four strain probiotic combination (HOWARU(&#xae;) Restore) on the incidence of AAD and CDAD and severity of gastrointestinal symptoms in adult in-patients requiring antibiotic therapy. Patients (n=503) were randomized among three study groups: HOWARU(&#xae;) Restore probiotic 1.70&#xd7;10(10) CFU (high-dose, n=168), HOWARU(&#xae;) Restore probiotic 4.17&#xd7;10(9) CFU (low-dose, n=168), or placebo (n=167). Subjects were stratified by gender, age, and duration of antibiotic treatment. Study products were administered daily up to 7 days after the final antibiotic dose. The primary endpoint of the study was the incidence of AAD. Secondary endpoints included incidence of CDAD, diarrhea duration, stools per day, bloody stools, fever, abdominal cramping, and bloating. A significant dose-response effect on AAD was observed with incidences of 12.5, 19.6, and 24.6% with high-dose, low-dose, and placebo, respectively (p=0.02). CDAD was the same in both probiotic groups (1.8%) but different from the placebo group (4.8%; p=0.04). Incidences of fever, abdominal pain, and bloating were lower with increasing probiotic dose. The number of daily liquid stools and average duration of diarrhea decreased with higher probiotic dosage. The tested four strain probiotic combination appears to lower the risk of AAD, CDAD, and gastrointestinal symptoms in a dose-dependent manner in adult in-patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ouwehand</LastName><ForeName>Arthur C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Active Nutrition, DuPont Nutrition &amp; Health, Sokeritehtaantie 20, Kantvik 02460, Finland. Electronic address: arthur.ouwehand@danisco.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DongLian</LastName><ForeName>Cai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Changhai Hospital, No. 800, Xiangyin Road, Shanghai 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weijian</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Changhai Hospital, No. 800, Xiangyin Road, Shanghai 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sprim, 1 Daniel Burnham Court, Suite 100C, San Francisco, 94109, CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sprim China, 200 NingHai East Rd, Shanghai 200021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Tad</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>DuPont Nutrition &amp; Health USA, 3329 Agriculture Drive, Madison 53716, WI USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Larry E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Sprim, 1 Daniel Burnham Court, Suite 100C, San Francisco, 94109, CA USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016360" MajorTopicYN="N">Clostridioides difficile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004761" MajorTopicYN="N">Enterocolitis, Pseudomembranous</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibiotic associated diarrhea</Keyword><Keyword MajorTopicYN="N">Bifidobacterium lactis</Keyword><Keyword MajorTopicYN="N">Dose response</Keyword><Keyword MajorTopicYN="N">Lactobacillus acidophilus</Keyword><Keyword MajorTopicYN="N">Lactobacillus paracasei</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24291194</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2013.11.053</ArticleId><ArticleId IdType="pii">S0264-410X(13)01587-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>